Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

BACKGROUND: Anti-angiogenic therapy is known to induce a greater degree of hypoxia, including in glioblastoma (GBM). Evofosfamide (Evo) is a hypoxia-activated prodrug which is reduced, leading to the release of the alkylating agent bromo-isophosphoramide mustard. We assessed the safety, tolerability...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Brenner, Andrew, Zuniga, Richard, Sun, Jessica D, Floyd, John, Hart, Charles P, Kroll, Stew, Fichtel, Lisa, Cavazos, David, Caflisch, Laura, Gruslova, Aleksandra, Huang, Shiliang, Liu, Yichu, Lodi, Alessia, Tiziani, Stefano
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071657/
https://ncbi.nlm.nih.gov/pubmed/29415215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars